Companies › Jiangsu HengRui Medicine
50 active drug programs in 389 registered trials: 187 Phase 2, 84 Phase 3, 66 Phase 1, 52 Phase 4; Oncology, Other, Immunology, Metabolic and endocrine; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Bupivacaine Sodium channel protein type IV alpha subunit blocker | Ion channels | Phase 4 | Local Analgesia Via Infiltration; Local Analgesia Via Nerve Block; Robotic Lung Surgery; Low Back Pain … | Nov 2026 |
| SHR-A1811 for Injection HER2-targeted antibody-drug conjugate | ERBB2 | Phase 3 | HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane; Non-Small Cell Lung Cancer With HER2- Mutations; Ovarian Cancer; HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma … | Nov 2026 |
| SHR0302 JAK1 inhibitor | JAK1 | Phase 3 | Psoriatic Arthritis; Non-segmental Vitiligo | Dec 2026 |
| Lutetium (177Lu) Oxodotreotide Injection Somatostatin receptor 2 (SSTR2)-targeting peptide radionuclide therapy | SSTR2 | Phase 3 | Advanced Gastroenteropancreatic Neuroendocrine Tumor | Dec 2026 |
| Pyrotinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor | EGFR, ERBB2 | Phase 3 | Breast Cancer; Advanced Non-small Cell Lung Cancer; HER2-positive Breast Cancer; Metastatic Breast Cancer … | Dec 2026 |
| Fuzuloparib PARP inhibitor | PARP1, PARP2 | Phase 3 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Dec 2026 |
| [14C]HRS-9190 Neuromuscular blocking agent | – | Phase 3 | Neuromuscular Blockade; Healthy Adult Male | Dec 2026 |
| FH-006 for Injection | – | Phase 3 | Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy; Lung Cancer; Malignant Solid Tumor | Feb 2027 |
| HRS-4642 KRAS G12D inhibitor | KRAS | Phase 3 | KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting; Advanced KRAS G12D Mutant Solid Tumors; Advanced Solid Tumors; Metastatic Pancreatic Carcinoma … | Mar 2027 |
| Rezvilutamide Androgen Receptor antagonist | AR | Phase 3 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Prostate Cancer; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Prostate Cancer (Post Prostatectomy) … | Mar 2027 |
| Famitinib Stem cell growth factor receptor inhibitor; Vascular endothelial growth factor receptor 1 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | KIT, FLT1, FLT3, PDGFRB, PDGFRA | Phase 3 | Cervical Cancer; Triple-Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Neoplasm … | May 2027 |
| camrelizumab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Gastric Cancer; Hepatocellular Carcinoma; Hepatocellular Carcinoma (HCC); Cervical Cancer … | May 2027 |
| HRS-4357 injection PSMA-targeting therapy (likely anti-PSMA antibody-drug conjugate or radioligand) | – | Phase 3 | PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer | Dec 2027 |
| SHR2554 HDAC inhibitor | – | Phase 3 | Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy; Advanced Gastric Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer; Prostate Cancer | Dec 2027 |
| Hetrombopag Olamine Thrombopoietin receptor agonist | MPL | Phase 3 | Chemotherapy-Induced Thrombocytopenia; Patients With Chemotherapy-Induced Thrombocytopenia; ITP - Immune Thrombocytopenia; Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors … | Dec 2028 |
| SHR6390 CDK4/6 inhibitor | CDK4, CDK6 | Phase 3 | Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage,Female Breast Cancer | Oct 2031 |
| HRS-8427 Carbapenem antibiotic | – | Phase 3 | Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP); Hospital-acquired Bacterial Pneumonia (HABP) | – |
| Rivoceranib Mesylate Vascular endothelial growth factor receptor 2 inhibitor | KDR | Phase 3 | Gastric Cancer; Hepatocellular Carcinoma; Hepatocellular Carcinoma (HCC); BCLC Stage C Hepatocellular Carcinoma … | – |
| HR070803 | – | Phase 2 | Colorectal Cancer | Dec 2026 |
| SHR-3167 Injection GLP-1 receptor agonist | – | Phase 2 | Type 2 Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetes Mellitus; Type 2 Diabetes | Dec 2026 |
| SHR-A1904 | – | Phase 2 | Advanced Gastric Cancer; Advanced Solid Tumors | Mar 2027 |
| Shr-4640 (SHR4640) Solute carrier family 22 member 12 inhibitor | SLC22A12 | Phase 2 | Primary Gout and Hyperuricemia | Jul 2027 |
| HRS-4508 tablet KRAS inhibitor | – | Phase 2 | Solid Tumor; Lung Cancer; Advanced Solid Tumors | Sep 2027 |
| Bevacizumab (BP102) Vascular endothelial growth factor A inhibitor | VEGFA | Phase 2 | Lung Cancer | Nov 2027 |
| RSS0343 tablets CFTR potentiator | – | Phase 2 | Adolescent Asthma | Nov 2027 |
| SHR-8068 | – | Phase 2 | Lung Cancer | Nov 2027 |
| SHR-1701 | – | Phase 2 | Advanced Gastric Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer | Dec 2027 |
| Trastuzumab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 2 | Unresectable Locally Recurrent Breast Cancer | Jun 2028 |
| Adabelimumab TWEAK/TNF superfamily ligand antagonist | TNFSF12 | Phase 2 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | Oct 2028 |
| SHR0302Base gel | – | Phase 2 | Vitiligo | – |
| HRS-2189 | – | Phase 1 | Breast Cancer | Dec 2026 |
| HRS-5041 tablets | – | Phase 1 | Advanced Prostate Cancer; Prostate Cancer | Dec 2026 |
| HRS-6209 CDK4/6 inhibitor | – | Phase 1 | Breast Cancer; Advanced Solid Tumors; Advanced Unresectable or Metastatic Breast Cancer | Dec 2026 |
| HRS-3738 | – | Phase 1 | Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma | Dec 2026 |
| HRS-1167 | – | Phase 1 | Advanced Solid Tumors; Prostate Cancer; BRCA-Mutated Breast Carcinoma | Dec 2026 |
| AG | – | Phase 1 | Advanced Solid Tumors; Borderline Resectable Pancreatic Adenocarcinoma | Mar 2027 |
| SHR-4394 | – | Phase 1 | Prostate Cancer | Mar 2027 |
| SHR-A1921 | – | Phase 1 | Advanced Solid Tumors | Mar 2027 |
| HRS-6768 | – | Phase 1 | Advanced Solid Tumors | Apr 2027 |
| HRS-9813 Unclear mechanism - requires further characterization | – | Phase 1 | Advanced Unresectable or Metastatic Breast Cancer | Dec 2027 |
| HRS-6093 KRAS G12D inhibitor | KRAS | Phase 1 | Advanced KRAS G12D Mutant Solid Tumors | May 2028 |
| HRS-7525 | – | Phase 1 | Prostate Cancer | Jun 2028 |
| HRS-3005 | – | Phase 1 | B-cell Malignancy | Oct 2028 |
| HRS-2329 RAS inhibitor | – | Phase 1 | Advanced Solid Tumors Harboring RAS Mutations or Amplifications | Dec 2028 |
| HRS-7172 RAS inhibitor | – | Phase 1 | Advanced Solid Tumors Harboring RAS Mutations or Amplifications; Pancreatic Cancer | Dec 2028 |
| HRS-8364 | – | Phase 1 | Solid Tumor | Dec 2028 |
| SHR-1049 Injection | – | Phase 1 | Advanced Solid Tumor | Dec 2028 |
| HRS-717 Unclear - code-named drug | – | Phase 1 | Pancreatic Cancer | Dec 2028 |
| HRS-6213 PET imaging agent | – | Phase 1 | Patients With Solid Tumors | – |
| RSS0393 ointment | – | Phase 1 | Healthy | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03906617 | Bupivacaine | Phase 4 | Robotic Lung Surgery | Other | Apr 2022 |
| NCT04704297 | Bupivacaine | Phase 4 | Low Back Pain | Other | Jul 2022 |
| NCT05533463 | HRS-4642 | Phase 1 | Advanced KRAS G12D Mutant Solid Tumors | Oncology | Jun 2024 |
| NCT06806410 | Bupivacaine | Phase 4 | Hand Surgery | Other | Nov 2024 |
| NCT05218889 | camrelizumab | Phase 1 | Pancreatic Cancer | Oncology | Dec 2024 |
| NCT06783764 | Bupivacaine | Phase 4 | Post Operative Analgesia | Other | Feb 2025 |
| NCT05864014 | Hetrombopag Olamine | Phase 3 | Chemotherapy-Induced Thrombocytopenia | Hematology | Mar 2025 |
| NCT04680221 | Bupivacaine | Phase 4 | Pain, Postoperative | Psychiatry | Jun 2025 |
| NCT05605639 | Bupivacaine | Phase 4 | Chronic Neck Pain | Other | Jul 2025 |
| NCT04521153 | camrelizumab | Phase 2 | Hepatocellular Carcinoma | Oncology | Jul 2025 |
| NCT04521153 | Rivoceranib Mesylate | Phase 2 | Hepatocellular Carcinoma | Oncology | Jul 2025 |
| NCT06569953 | Bupivacaine | Phase 4 | Acute Pain | Other | Aug 2025 |
| NCT07178262 | Bupivacaine | Phase 4 | Erector Spinae Block | Other | Oct 2025 |
| NCT06719180 | Bupivacaine | Phase 4 | Hysterectomy | Other | Oct 2025 |
| NCT06753500 | Bupivacaine | Phase 4 | Visceral Pain | Psychiatry | Nov 2025 |
| NCT05224089 | Bupivacaine | Phase 4 | Bowel Disease | Gastroenterology | Nov 2025 |
| NCT07065435 | Pyrotinib | Phase 2 | HER2 + Breast Cancer | Oncology | Dec 2025 |
| NCT06385678 | HRS-4642 | Phase 1 | Advanced KRAS G12D Mutant Solid Tumors | Oncology | Dec 2025 |
| NCT06308393 | RSS0393 ointment | Phase 1 | Healthy | Immunology | Dec 2025 |
| NCT05602636 | Bupivacaine | Phase 4 | Forearm Surgery | Other | Dec 2025 |
| NCT04560127 | camrelizumab | Phase 2 | Radioactive Iodine-refractory Differentiated Thyroid Cancer | Oncology | Dec 2025 |
| NCT07070349 | HRS-6213 | Phase 1 | Patients With Solid Tumors | Oncology | Jan 2026 |
| NCT06165991 | Bupivacaine | Phase 4 | Thoracic Paravertebral Block | Other | Jan 2026 |
| NCT07018453 | SHR-3167 Injection | Phase 2 | Type 2 Diabetes Mellitus | Metabolic and endocrine | Feb 2026 |
| NCT07051486 | SHR-A1811 for Injection | Phase 2 | Recurrent or Metastatic Cervical Cancer | Oncology | Feb 2026 |
| NCT06790862 | SHR0302Base gel | Phase 2 | Vitiligo | Immunology | Mar 2026 |
| NCT06947330 | Bupivacaine | Phase 3 | Modified Radical Mastectomy | Oncology | Mar 2026 |
| NCT06947330 | Bupivacaine | Phase 3 | Modified Radical Mastectomy | Oncology | Mar 2026 |
| NCT07482709 | Bupivacaine | Phase 1 | Post Operative Pain in Total Abdominal Hystrectomy | Other | Mar 2026 |
| NCT04342910 | camrelizumab | Phase 3 | Gastric Cancer | Oncology | Apr 2026 |
| NCT04342910 | Rivoceranib Mesylate | Phase 3 | Gastric Cancer | Oncology | Apr 2026 |
| NCT06353529 | Bupivacaine | Phase 4 | Pituitary | Metabolic and endocrine | Apr 2026 |
| NCT06349317 | camrelizumab | Phase 2 | Hepatocellular Carcinoma | Oncology | May 2026 |
| NCT06122389 | SHR2554 | Phase 3 | Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy | Oncology | May 2026 |
| NCT05277168 | SHR-A1904 | Phase 1 | Advanced Solid Tumors | Oncology | May 2026 |
| NCT07494175 | [14C]HRS-9190 | Phase 1 | Healthy Adult Male | Other | May 2026 |
| NCT06817525 | camrelizumab | Phase 2 | Triple-negative Breast Cancer | Oncology | May 2026 |
| NCT06565910 | Bupivacaine | Phase 4 | Femoral Neck Fractures | Other | Jun 2026 |
| NCT07090928 | Bupivacaine | Phase 4 | Arthroscopic Surgery | Other | Jun 2026 |
| NCT06714279 | Bupivacaine | Phase 1 | Laparoscopic Cholecystectomy | Other | Jun 2026 |
| NCT07429448 | Bupivacaine | Phase 1 | Appendectomy | Other | Jun 2026 |
| NCT07409688 | Bupivacaine | Phase 4 | Laparoscopic Cholecystectomy Surgery | Other | Jun 2026 |
| NCT05391971 | Bupivacaine | Phase 4 | Post Traumatic Stress Disorder | Psychiatry | Jun 2026 |
| NCT05198609 | camrelizumab | Phase 3 | Hepatocellular Carcinoma | Oncology | Jul 2026 |
| NCT07492693 | Hetrombopag Olamine | Phase 2 | Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors | Oncology | Jul 2026 |
| NCT05320692 | camrelizumab | Phase 3 | Hepatocellular Carcinoma | Oncology | Jul 2026 |
| NCT05320692 | Rivoceranib Mesylate | Phase 3 | Hepatocellular Carcinoma | Oncology | Jul 2026 |
| NCT07049835 | Bupivacaine | Phase 1 | Inguinal Hernias | Gastroenterology | Jul 2026 |
| NCT04639180 | camrelizumab | Phase 3 | Hepatocellular Carcinoma (HCC) | Oncology | Jul 2026 |
| NCT04639180 | Rivoceranib Mesylate | Phase 3 | Hepatocellular Carcinoma (HCC) | Oncology | Jul 2026 |
| NCT06639503 | Bupivacaine | Phase 1 | Tibial Plateau Fractures | Other | Sep 2026 |
| NCT06569056 | HRS-8427 | Phase 3 | Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) | Infectious disease | Sep 2026 |
| NCT07140640 | Bupivacaine | Phase 4 | Cesarean Section Complications | Other | Sep 2026 |
| NCT07610148 | HRS-6209 | Phase 1 | Breast Cancer | Oncology | Sep 2026 |
| NCT05942001 | HRS-5041 tablets | Phase 1 | Advanced Prostate Cancer | Oncology | Sep 2026 |
| NCT06841731 | HRS-8427 | Phase 2 | Hospital-acquired Bacterial Pneumonia (HABP) | Infectious disease | Sep 2026 |
| NCT04979338 | Bupivacaine | Phase 3 | Gender Dysphoria | Psychiatry | Sep 2026 |
| NCT06179004 | Bupivacaine | Phase 3 | Distal Radius Fractures | Other | Oct 2026 |
| NCT06711471 | camrelizumab | Phase 2 | Gastric Cancer Adenocarcinoma Metastatic | Oncology | Nov 2026 |
| NCT05176002 | camrelizumab | Phase 1 | Esophageal Neoplasm | Oncology | Nov 2026 |
The 60 nearest readouts of 389 trials; the rest in the app.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.